Business / Finance

RSS
Capsugel Nabs Bend Research

Capsugel Nabs Bend Research

5 Sep 2013
Sanofi To Commercialize Pozen Proton Pump Inhibitor/Aspirin Product

Sanofi To Commercialize Pozen Proton Pump Inhibitor/Aspirin Product

5 Sep 2013
Walgreens’ August sales increased by 5.6% to $6.17 billion

Walgreens’ August sales increased by 5.6% to $6.17 billion

5 Sep 2013
Patheon's Q3 2013 revenues increase 30.4% to $265.7 million

Patheon's Q3 2013 revenues increase 30.4% to $265.7 million

5 Sep 2013
ThromboGenics, Bicycle to develop and commercialize novel drugs for ophthalmic diseases

ThromboGenics, Bicycle to develop and commercialize novel drugs for ophthalmic diseases

5 Sep 2013
Neurodyn acquires all assets related to new drug candidate Memogain from Galantos Pharma

Neurodyn acquires all assets related to new drug candidate Memogain from Galantos Pharma

5 Sep 2013
Affinium initiates dosing in Phase 1 IV clinical trial of antibiotic prodrug, AFN-1720

Affinium initiates dosing in Phase 1 IV clinical trial of antibiotic prodrug, AFN-1720

5 Sep 2013
Sanofi, POZEN ink license agreement to commercialize PA8140 and PA32540 tablets in US

Sanofi, POZEN ink license agreement to commercialize PA8140 and PA32540 tablets in US

5 Sep 2013
Accelrys Buys Chemsw In Deal Worth Up To $17.3M

Accelrys Buys Chemsw In Deal Worth Up To $17.3M

4 Sep 2013
Repligen Earns $1M Pfizer Milestone Payment

Repligen Earns $1M Pfizer Milestone Payment

4 Sep 2013
Revived Genvec Withdraws Dissolution Plan; New CEO Named

Revived Genvec Withdraws Dissolution Plan; New CEO Named

4 Sep 2013
Ultragenyx, Kyowa Hakko Kirin To Develop Rare Bone Disease-Fighting Mab

Ultragenyx, Kyowa Hakko Kirin To Develop Rare Bone Disease-Fighting Mab

4 Sep 2013
Taconic To Promote And Sell Medicyte Hepatocyte Products

Taconic To Promote And Sell Medicyte Hepatocyte Products

4 Sep 2013
Rochester Medical enters into definitive merger agreement with C. R. Bard

Rochester Medical enters into definitive merger agreement with C. R. Bard

4 Sep 2013
Cangene Signs Up To $77M Contract Extension With CDC

Cangene Signs Up To $77M Contract Extension With CDC

3 Sep 2013
Enanta Gets Additional $9.2M Toward Biodefense Antibiotic Development

Enanta Gets Additional $9.2M Toward Biodefense Antibiotic Development

3 Sep 2013
Baxter, Coherus Ink Biosimilar Collaboration Worth Up To $246M

Baxter, Coherus Ink Biosimilar Collaboration Worth Up To $246M

3 Sep 2013
Cangene Inks Up To $77M Contract Extension With CDC

Cangene Inks Up To $77M Contract Extension With CDC

3 Sep 2013
Viralytics releases financial results for 2013

Viralytics releases financial results for 2013

3 Sep 2013
Sanomedics completes acquisition of Prime Time Medical

Sanomedics completes acquisition of Prime Time Medical

3 Sep 2013

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback